Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma (Q39953997)

15 September 2017

1 reference

title

Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma (English)

1 reference

15 September 2017

1 reference

Comis RL

1

1 reference

PubMed ID

4619579

15 September 2017

Carter SK

series ordinal

2

1 reference

15 September 2017

1 December 1974

1 reference

15 September 2017

Cancer Treatment Reviews

1 reference

15 September 2017

1

1 reference

15 September 2017

4

1 reference

15 September 2017

285-304

1 reference

Neoplastic disease. Treatment with vinblastine. A cooperative study

15 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Evaluation of 1-(2-chloroethyl-3-4-methylcyclohexyl)-1-nitrosourea (methyl-CCNU, NSC 95441) versus combined imidazole carboxamide (NSC 45338) and vincristine (NSC 67574) in palliation of disseminated malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Therapeutic effects of hydroxyurea.Experience with 118 patients with inoperable solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

The absorption and metabolism of dibromodulcitol in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

VINBLASTINE SULPHATE IN THE TREATMENT OF MALIGNANT DISEASE.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Adriamycin. A new anticancer drug with significant clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

A clinical review of bleomycin--a new antineoplastic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Hexamethylmelamine--a new drug with activity in solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Immunological Effects of BCG in Malignant Melanoma: Two Modes of Administration Compared

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Treatment of neoplastic diseases with an improved oral preparation of vinblastine sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

FURTHER COMPARATIVE TRIAL OF TRIETHYLENE THIOPHOSPHORAMIDE AND MECHLORETHAMINE IN PATIENTS WITH MELANOMA AND HODGKIN'S DISEASE

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

1-2(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, NSC-79037): a comparison of drug administration at four-week and six-week intervals

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

A METHYLHYDRAZINE DERIVATIVE IN HODGKIN'S DISEASE AND OTHER MALIGNANT NEOPLASMS. THERAPEUTIC AND TOXIC EFFECTS STUDIED IN 51 PATIENTS.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Imidazole carboxamide therapy in advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)—A new antitumor agent with activity against malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Integration of chemotherapy into combined modality treatment of solid tumors. 1. The overall strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Combined actinomycin D and vincristine in the treatment of patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

ORAL MELPHALAN THERAPY IN ADVANCED MALIGNANT DISEASE.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Clinical evaluation of a new alkylating agent: cytoxan (cyclophosphamide)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Triple combination chemotherapy of disseminated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Therapy of malignant melanoma with an imidazole carboxamide and bis-chloroethyl nitrosourea

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-fluorouracil in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Management of adult acute myelogenous leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

The use of drugs in combination for the treatment of cancer: rationale and results

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Preliminary clinical studies with ibenzmethyzin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Chemotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and dactinomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Clinical experience with mitomycin C in large infrequent doses

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Induced remission of malignant melanoma with actinomycin D.Immunologic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Clinical Evaluation of 5-(3,3-Dimethyl-1-Triazeno) Imidazole-4-Carboxamide in Malignant Melanoma and Other Neoplasms: Comparison of Twice-weekly and Daily Administration Schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Active immunotherapy with B.C.G. for recurrent malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Seventy-Five Cases of Solid Tumours Treated by a Modified Quadruple Chemotherapy Regime

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Studies of phenylalanine nitrogen mustard (CB 3025) in metastatic malignant melanoma of man

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer. Phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Chemotherapy of metastatic malignant melanoma. Experience with 73 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Improved systemic chemotherapy for malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

BCNU (1,3), BIS(B-chloroethyl)-1-nitrosourea. Effects on advanced Hodgkin's disease and other neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Chemotherapy of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Combination chemotherapy in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Phase II evaluation of adriamycin in human neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Metastatic melanoma with indeterminate primary site. Report of two instances of long-term survival

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Studies of the mechanism of action of the antitumor agent 5(4)-(3,3-dimethyl-1-triazeno) imidazole-4(5)-carboxamide in Bacillus subtilis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Complete Inhibition of Mouse Leukaemia L1210 by 5(or 4)-[3,3-Mbis (2-Chloroethyl)-l-triazeno]imidazole-4(or 5)-carboxamide (NSC-82196)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Cyclophosphamide. A clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

NATULAN IN MANAGEMENT OF LATE HODGKIN'S DISEASE, OTHER LYMPHORETICULAR NEOPLASMS, AND MALIGNANT MELANOMA.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

TOXICITY AND ANTITUMOR EFFECT OF DIVIDED DOSES OF METHOTREXATE

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Combination phase 1-II study of imidazole carboxamide (NCS45388)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

Clinical studies of actinomycin D

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2874%2980020-4

7 January 2021

10.1016/S0305-7372(74)80020-4

Identifiers

DOI

1 reference

15 September 2017

1 reference

PubMed ID

4619579